whole-body PET imaging
Implementation of quadratic dose protocol for 18F-FDG whole-body PET imaging using a BGO-based PET/CT scanner, GE Discovery ST
8
Optimized dose regimen for whole-body FDG-PET imaging
11
Impact of PET acquisition durations on image quality and lesion detectability in whole-body 68Ga-PSMA PET-MRI
12
An Investigation of the Required MR Bone Attenuation Correction for Quantitative Whole Body PET/MR Imaging Using Clinical NaF PET/CT Studies
23
Impact of Integrated Whole Body 68Ga PET/MR Imaging in Comparison with 68Ga PET/CT in Lesions Detection and Diagnosis of Suspected Neuroendocrine Tumours
10
Positron Emission Tomography Reporter Genes and Reporter Probes: Gene and Cell Therapy Applications
18
MRI-Based Attenuation Correction in Emission Computed Tomography
226
Motion Correction of Whole-Body PET Data with a Joint PET-MRI Registration Functional
9
Clinical value of whole body PET/CT in patients with active rheumatic diseases
12
18F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition
7
Toxicity and radiation dosimetry studies of the serotonin transporter radioligand [18 F]AFM in rats and monkeys
12
A prospective study determining and comparing the diagnostic accuracy of fluoride-PET/CT, choline-PET/CT, whole-body bone SPECT/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer
15
Whole-body magnetic resonance imaging for the assessment of metastatic breast cancer
14
Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating whole–body magnetic resonance imaging in radio-recurrent prostate cancer
11
Chelator-Free Radiolabeling of SERRS Nanoparticles for Whole-Body PET and Intraoperative Raman Imaging
10
Effects of ferumoxytol on quantitative PET measurements in simultaneous PET/MR whole-body imaging: a pilot study in a baboon model
12
Whole-body MRI versus <sup>18</sup>F-FDG PET/CT for pretherapeutic assessment and staging of lymphoma: a meta-analysis
12
Qualitative and Quantitative Performance of 18F FDG PET/MRI versus 18F FDG PET/CT in Patients with Head and Neck Cancer
6
The future of hybrid imaging—part 2: PET/CT
10
PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders
9